Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy

Citadel Advisors bought 2.7 million AbbVie shares in Q2 at an average $234.57, investing about $633 million and bringing its stake to 3.2 million shares, worth about $909 million at the cited current price of $284. AbbVie has raised its annual dividend for 50 consecutive years; its $6.92 annual dividend implies a 2.43% yield, while its pipeline includes about 90 treatments in development, two-thirds in late-stage trials. The FDA approved Juvmo in September for Parkinson’s disease, and William Blair analysts project sales could reach $1.4 billion annually by 2040; the article also notes valuation at 74 times trailing earnings and a roughly 24% share-price rise this year.

Analysis

The key investment question is not whether AbbVie has a large pipeline, but whether newer products can replace legacy-product erosion quickly enough to sustain earnings expectations. If Skyrizi and Rinvoq keep gaining share, they can reduce the market’s dependence on Humira and support a durable cash-flow story; if uptake, access, or pricing disappoints, the pipeline count itself offers little valuation protection. Competition from other immunology franchises, including Johnson & Johnson and Eli Lilly, makes share and pricing trends more informative than headline market growth.

Near term, Citadel’s reported purchase is weak evidence of fresh directional conviction: a 13F is delayed and does not reveal associated shorts or hedges. The heavily positive analyst stance may also leave less room for upside surprise. Over 1–3 months, focus on product-level sales, guidance, and any updates to the claimed Parkinson’s-drug launch. Verify the drug’s approval status, launch timing, and commercial assumptions before underwriting the cited long-range sales potential. Over 6–18 months, the thesis depends on newer products offsetting legacy erosion and late-stage programs converting into approved, revenue-producing medicines.

The contrarian risk is that a defensive dividend profile can obscure growth expectations embedded in the share price; trailing P/E alone is not a sound valuation measure without understanding the earnings denominator. No compelling trade follows from the article alone. Reassess after earnings or a material product update, when replacement growth and valuation can be tested against reported results.

Key Decisions for Investors

• Do not add ABBV solely on Citadel’s disclosed stake or the dividend record; treat the filing as lagged positioning information, not a standalone catalyst.
• Watch the next earnings release for Skyrizi/Rinvoq growth, Humira-related erosion, and any guidance changes. A slowdown in replacement-product growth or weaker guidance would falsify the constructive thesis and argue against adding exposure.
• Before crediting the Parkinson’s asset with meaningful value, verify FDA status, launch progress, and the source and assumptions behind the long-term sales estimate; treat it as an alert, not an earnings catalyst, until confirmed.
• If already long, avoid chasing a sharp sentiment-driven move; reassess after earnings. A relative-value comparison with large-cap pharma peers may be more appropriate than a broad biotech trade, but requires current valuation and product-growth data not supplied here.